Reply to Chao and Lai.

Autor: Wunderink RG; Department of Medicine, Division of Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Roquilly A; Université de Nantes, Centre Hospitalier Universitaire de Nantes, EA3826 Thérapeutiques Anti-Infectieuses, Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes, France., Croce M; Regional One Health, Memphis, Tennessee, USA., Gonzalez DR; Department of Intensive Care, Nuevo Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico., Fujimi S; Department of Trauma, Critical Care, and Emergency Medicine, Osaka General Medical Center, Sumiyoshi-ku, Osaka, Japan., Butterton JR; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA., Broyde N; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA., Popejoy MW; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA., Kim JY; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA., De Anda C; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Jazyk: angličtina
Zdroj: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Oct 20; Vol. 73 (8), pp. 1552-1553.
DOI: 10.1093/cid/ciab391
Databáze: MEDLINE